###begin article-title 0
Calpain-5 gene variants are associated with diastolic blood pressure and cholesterol levels
###end article-title 0
###begin p 1
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
###end p 1
###begin title 2
Background
###end title 2
###begin p 3
###xml 502 507 502 507 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CAPN5</italic>
###xml 548 554 548 554 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CAPN5 </italic>
###xml 669 675 669 675 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CAPN5 </italic>
###xml 415 420 <span type="species:ncbi:9606">women</span>
Genes implicated in common complex disorders such as obesity, type 2 diabetes mellitus (T2DM) or cardiovascular diseases are not disease specific, since clinically related disorders also share genetic components. Cysteine protease Calpain 10 (CAPN10) has been associated with T2DM, hypertension, hypercholesterolemia, increased body mass index (BMI) and polycystic ovary syndrome (PCOS), a reproductive disorder of women in which isunlin resistance seems to play a pathogenic role. The calpain 5 gene (CAPN5) encodes a protein homologue of CAPN10. CAPN5 has been previously associated with PCOS by our group. In this new study, we have analysed the association of four CAPN5 gene variants(rs948976A>G, rs4945140G>A, rs2233546C>T and rs2233549G>A) with several cardiovascular risk factors related to metabolic syndrome in general population.
###end p 3
###begin title 4
Methods
###end title 4
###begin p 5
###xml 439 444 439 444 <italic xmlns:xlink="http://www.w3.org/1999/xlink">loci </italic>
###xml 447 453 447 453 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CAPN5 </italic>
Anthropometric measurements, blood pressure, insulin, glucose and lipid profiles were determined in 606 individuals randomly chosen from a cross-sectional population-based epidemiological survey in the province of Segovia in Central Spain (Castille), recruited to investigate the prevalence of anthropometric and physiological parameters related to obesity and other components of the metabolic syndrome. Genotypes at the four polymorphic loci in CAPN5 gene were detected by polymerase chain reaction (PCR).
###end p 5
###begin title 6
Results
###end title 6
###begin p 7
###xml 156 162 154 160 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CAPN5 </italic>
Genotype association analysis was significant for BMI (p </= 0.041), diastolic blood pressure (p = 0.015) and HDL-cholesterol levels (p = 0.025). Different CAPN5 haplotypes were also associated with diastolic blood pressure (DBP) (0.0005 </= p </= 0.006) and total cholesterol levels (0.001 </= p </= 0.029). In addition, the AACA haplotype, over-represented in obese individuals, is also more frequent in individuals with metabolic syndrome defined by ATPIII criteria (p = 0.029).
###end p 7
###begin title 8
Conclusion
###end title 8
###begin p 9
###xml 17 23 17 23 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CAPN10</italic>
###xml 25 31 25 31 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CAPN5 </italic>
###xml 141 147 141 147 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CAPN5 </italic>
As its homologue CAPN10, CAPN5 seems to influence traits related to increased risk for cardiovascular diseases. Our results also may suggest CAPN5 as a candidate gene for metabolic syndrome.
###end p 9
###begin title 10
Background
###end title 10
###begin p 11
###xml 349 350 349 350 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
Factors that increase the risk of cardiovascular disease (CVD) include obesity, dyslipidemia, glucose intolerance, type 2 diabetes mellitus (T2DM) and hypertension. When these factors cluster in an individual is called metabolic syndrome (MS), a complex disorder characterized by impaired glucose metabolism, dyslipidemia, hypertension and obesity [1].
###end p 11
###begin p 12
###xml 226 227 226 227 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 339 340 339 340 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 764 774 764 774 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C.elegans </italic>
###xml 857 858 857 858 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 859 860 859 860 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 1095 1096 1095 1096 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 1097 1098 1097 1098 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 1182 1192 1182 1192 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C.elegans </italic>
###xml 1339 1340 1339 1340 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 1358 1364 1358 1364 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FEM1A </italic>
###xml 1769 1770 1769 1770 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 1831 1837 1831 1837 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FEM1A </italic>
###xml 1922 1928 1922 1928 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FEM1A </italic>
###xml 234 239 <span type="species:ncbi:9606">human</span>
###xml 764 773 <span type="species:ncbi:6239">C.elegans</span>
###xml 889 894 <span type="species:ncbi:9606">human</span>
###xml 1129 1133 <span type="species:ncbi:10090|species:ncbi:10095">mice</span>
###xml 1182 1191 <span type="species:ncbi:6239">C.elegans</span>
###xml 1346 1352 <span type="species:ncbi:9606">humans</span>
###xml 1481 1486 <span type="species:ncbi:9606">women</span>
###xml 1852 1857 <span type="species:ncbi:9606">woman</span>
Calpains are a class of cysteine proteases that requires calcium for its activation. They are implicated in a wide range of cellular functions, including apoptosis, intracellular signalling, proliferation and differentiation [2]. The human calpain family currently comprises 16 members and two subfamilies based on its functional domains [3]. The classic calpains are heterodimeric proteins that contain five sets of EF-hand calcium-binding structures in each subunit, similar to those in calmodulin. Calpain 10 (CAPN10), calpain 5 (CAPN5) and calpain 6 (CAPN6) proteins belong to the non-EF-hand subfamily that lacks these calcium-binding motifs; these calpains also differ from the remaining members of this subfamily in the presence of a T-domain homologous to C.elegans TRA-3, a protein implicated in the sexual determination of the hermaphrodite worm [4,5]. In fact, calpain 5 is the human ortologue of the TRA-3 nematode protein, a protease that exerts its action over a transmembrane protein called TRA-2 which binds and inhibits the male promoting FEM proteins (FEM-1, FEM-2 and FEM-3) [6,7]. Interestingly, the knockout mice of one of the three mammalian homologues of the C.elegans fem-1 gene, Fem1b, display abnormal glucose homeostasis, with abnormal glucose tolerance tests and defective glucose-stimulated insulin secretion [8]. In humans, the FEM1A gene maps to chromosome 19p13.3, a region linked to polycystic ovary syndrome (PCOS), a common endocrine disorder of women of reproductive age, characterized by chronic anovulation, infertility, hyperandrogenemia and frequently, insulin resistance resulting in an increased prevalence of obesity, CVD and T2DM, reason why PCOS is consider a phenotype closely related to metabolic syndrome. Maher y cols. [9] have recently reported a germline missense mutation in the FEM1A gene in a PCOS woman that was absent in 198 control chromosomes; the authors propose FEM1A as a candidate gene for PCOS.
###end p 12
###begin p 13
###xml 4 10 4 10 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CAPN5 </italic>
###xml 20 27 20 27 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CAPN10 </italic>
###xml 67 73 67 73 <italic xmlns:xlink="http://www.w3.org/1999/xlink">locus </italic>
###xml 85 90 85 90 <italic xmlns:xlink="http://www.w3.org/1999/xlink">et al</italic>
###xml 93 95 93 95 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 198 200 198 200 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 201 203 201 203 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 221 223 221 223 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 240 242 240 242 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 283 290 283 290 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CAPN10 </italic>
###xml 322 329 322 329 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CAPN10 </italic>
###xml 461 463 461 463 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 479 486 479 486 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CAPN10 </italic>
###xml 580 582 580 582 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 583 585 583 585 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 451 459 <span type="species:ncbi:9606">patients</span>
The CAPN5 homologue CAPN10 was identified as a T2DM susceptibility locus by Horikawa et al. [10] and has been shown to be related to proinsulin processing, insulin secretion and insulin resistance [11,12]. Ehrman et al. [13] and our group [14] independently published association of CAPN10 gene with PCOS. A reanalysis of CAPN10 gene in a larger PCOS population, allowed us to identify specific haplotypes associated with hypercholesterolemia in PCOS patients [15]. Furthermore, CAPN10 has been associated with hypertension and elevated body mass index (BMI) by different groups [16,17].
###end p 13
###begin p 14
###xml 37 43 37 43 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CAPN5 </italic>
###xml 123 125 123 125 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 151 157 151 157 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CAPN5 </italic>
###xml 242 248 242 248 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CAPN5 </italic>
###xml 517 523 517 523 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CAPN5 </italic>
###xml 597 602 597 602 <italic xmlns:xlink="http://www.w3.org/1999/xlink">et al</italic>
###xml 605 607 605 607 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 701 707 701 707 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CAPN5 </italic>
###xml 116 121 <span type="species:ncbi:9606">women</span>
###xml 197 205 <span type="species:ncbi:9606">patients</span>
###xml 317 325 <span type="species:ncbi:9606">patients</span>
In a previous work, we analyzed four CAPN5 gene variants (rs948976, rs4945140, rs2233546 and rs2233549) in 148 PCOS women [18]. We found that specific CAPN5 haplotypes were overrepresented in PCOS patients. In addition, we identified several CAPN5 alleles associated with phenotypic differences observed between PCOS patients, such as the presence of obesity, cardiovascular complications, and familial antecedents of obesity, hypertension and T2DM aggregation. These findings aimed us to investigate the relation of CAPN5 gene with cardiovascular risk factors in the general population. Silander et al. [19] have reported strong evidence of linkage within 11q14, the chromosomal region that contains CAPN5 gene in a large set of Finnish affected sibling pair families with T2DM.
###end p 14
###begin p 15
###xml 67 73 67 73 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CAPN5 </italic>
###xml 181 187 181 187 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CAPN5 </italic>
###xml 274 280 274 280 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CAPN5 </italic>
Here we present the first population-based association analysis of CAPN5 gene in traits related to hypertension and other components of metabolic syndrome. Our results suggest that CAPN5 alleles could modulate diastolic blood pressure and cholesterol levels. In addition, a CAPN5 haplotype over-represented in obese individuals is also associated with the cluster of cardiovascular risk factors defined as metabolic syndrome.
###end p 15
###begin title 16
Methods
###end title 16
###begin title 17
###xml 0 8 <span type="species:ncbi:9606">Patients</span>
Patients
###end title 17
###begin p 18
###xml 424 426 424 426 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 496 497 496 497 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 63 66 <span type="species:ncbi:9606">men</span>
###xml 86 91 <span type="species:ncbi:9606">women</span>
This population based study included 606 non-related Caucasian men (n = 278, 46%) and women (n = 328, 54%) recruited by a simple random sampling approach from a cross-sectional population-based epidemiological survey in the province of Segovia in Central Spain (Castille) aimed at investigating the prevalence of anthropometric and physiological parameters related to obesity and other components of the metabolic syndrome [20]. Clinical characteristics of study subjects are summarized in table 1. Individuals with previous diagnosis of type 1 diabetes were excluded from the study.
###end p 18
###begin p 19
Clinical characteristics of study subjects
###end p 19
###begin p 20
All study subjects gave their written consent to participate in the study. The study protocol was approved by the Ethics Committee of the Hospital Clinico San Carlos of Madrid.
###end p 20
###begin title 21
Phenotype measurements
###end title 21
###begin p 22
###xml 54 60 54 60 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CAPN5 </italic>
We have analysed the existence of association between CAPN5 and twelve clinical parameters: body mass index (BMI), waist circumference (WC), systolic and diastolic blood pressures (SBP, DBP), fasting glucose, 2-hours glucose, fasting insulin, insulin resistance (IR-HOMA), total cholesterol, HDL-cholesterol, LDL-cholesterol and triglycerides (TGs).
###end p 22
###begin p 23
SBP and DBP were measured three times in the seated position after 10 minutes of rest to the nearest even digit by use of a random-zero sphygmomanometer.
###end p 23
###begin p 24
###xml 542 547 <span type="species:ncbi:9606">Human</span>
After an overnight fast period, 20 ml of blood were obtained from an antecubital vein without compression. Plasma glucose was determined in duplicate by a glucose-oxidase method adapted to an Autoanalyzer (Hitachi 704, Boehringer Mannheim, Germany). Total cholesterol, triglycerides and high-density lipoprotein (HDL) cholesterol were determined by enzymatic methods using commercial kits (Boehringer Mannheim, Germany). Low-density lipoprotein (LDL) cholesterol was calculated by the Friedewald formula. Serum insulin was determined by RIA (Human Insulin Specific RIA kit, Linco Research Inc., St Louis MO, USA).
###end p 24
###begin p 25
###xml 273 275 273 275 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
Oral glucose tolerance test (OGTT) using 75 g of glucose was performed according to the WHO recommendations. Two hours after glucose administration, blood samples were obtained for the determination of glucose levels and interpreted the results according to Genuth et al. [21]. The crude prevalences of T2DM, impaired fasting glucose (IFG) and impaired glucose tolerance (IGT) were respectively 8.7%, 13.6% and 15.0%.
###end p 25
###begin p 26
###xml 152 154 152 154 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
Insulin resistance was estimated by the homeostasis model assessment (HOMA-IR) method according to the formula: Insulin (mU/l) x Glucose (mmol/l)/22.5 [22].
###end p 26
###begin p 27
###xml 354 356 346 348 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
###xml 530 532 522 524 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 185 188 <span type="species:ncbi:9606">men</span>
###xml 196 201 <span type="species:ncbi:9606">women</span>
###xml 296 299 <span type="species:ncbi:9606">men</span>
###xml 312 317 <span type="species:ncbi:9606">women</span>
###xml 607 610 <span type="species:ncbi:9606">men</span>
###xml 629 634 <span type="species:ncbi:9606">women</span>
The metabolic syndrome status was established according to ATPIII definition as it was recently modified: presence of at least three components between abdominal obesity (WC >/= 102 cm men, 88 cm women), hypertriglyceridemia (TGs >/= 150 mg/dl), hypertension (>/= 85/130 mmHg), HDL-c (< 40 mg/dl men, < 50 mg/dl women) and fasting glucose >/= 100 mg/dl [23]. We have also classified subjects according to the recently International Diabetes Federation (IDF) worldwide definition of the metabolic syndrome for Europid populations [24]. In this last definition, central adiposity (defined as WC >/= 94 cm for men and >/= 80 cm for women) is a prerequisite risk factor for the diagnosis of the syndrome; two of the following factors are also necessary: raised TG level (>150 mg/dl) or specific treatment for this abnormality; reduced HDL-c (< 40 mg/dl males, < 50 mg/dl females) or specific treatment; raised blood pressure (SBP >/= 130 or DBP >/= 85) or treatment of previously diagnosed hypertension, raised fasting plasma glucose (FPG >/= 100 mg/dl) or previously diagnosed T2DM. The crude prevalence of metabolic syndrome under ATPIII criteria is 12.6% and 19.8% under IDF definition.
###end p 27
###begin title 28
DNA extraction
###end title 28
###begin p 29
DNA extraction from 5 ml of frozen peripheral blood was performed in a MagNa Pure LC Instrument (Roche Diagnostics), using MagNa Pure LC DNA Isolation kits (Roche Diagnostics) according to the manufacturer's instructions. Aliquots of DNA of 5 ng/ul were obtained to carry out PCR reactions.
###end p 29
###begin title 30
Genotyping
###end title 30
###begin p 31
###xml 130 136 130 136 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CAPN5 </italic>
###xml 181 182 181 182 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1</xref>
###xml 311 317 311 317 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CAPN5 </italic>
###xml 546 548 546 548 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 636 638 636 638 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
We have analysed two polymorphisms in intron 1 (rs948976 A>G and rs4945140 G>A) and two polymorphisms located in the, intron 3 of CAPN5 gene (rs223546 C>T and rs223549 G>A) (Figure 1). These last two SNPs are located in the coding region of the OMP gene, an intronic gene integrated in the non-coding region of CAPN5 gene, so the aminoacids encoded by the OMP gene are not present in the CAPN5 protein. These SNPs were selected because they had been associated with PCOS, an insulin resistance related phenotype, in a previous work by our group [18]. The genotyping of the selected SNPs was performed according to described procedures [18].
###end p 31
###begin p 32
###xml 10 16 10 16 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CAPN5 </italic>
###xml 52 58 52 58 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CAPN5 </italic>
Scheme of CAPN5 gene organization and LD pattern of CAPN5 with neighboring genes (region spanning 140 kb aproximately). Analysed polymorphism are indicated by triangles.
###end p 32
###begin title 33
Statistical analysis
###end title 33
###begin p 34
###xml 220 222 220 222 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
###xml 311 313 311 313 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B26">26</xref>
###xml 278 283 <span type="species:ncbi:9606">Human</span>
To analyze differences in genotype distribution, chi-squared association studies for metabolic syndrome, T2DM, IFG and IGT and test for deviation from Hardy-Weinberg equilibrium, we have used tests adapted from Sasieni [25] at the online resource available at the Institute for Human Genetics, Munich, Germany [26] or SPSS software (Ver. 11.0.0., LEAD Technologies, Inc).
###end p 34
###begin p 35
For genotype quantitative analysis, we have performed an analysis of variance using the GLM procedure included in SPSS software (Ver. 11.0.0., LEAD Technologies, Inc). Normality of the dependent variables was assessed by Kolmogorov-Smirnov test and, when necessary, we applied mathematical transformations (natural logarithm or inverse of the square root) prior to the analysis. Each analysis was adjusted for age and sex. The adjusted percentage of the phenotypic variance explained by each genotype was estimated by subtracting the adjusted r2 value for a model that includes the genotype from the r2 for a model that excludes it. The Levene's test of equality of error variances was also performed for each analysis. In addition, all values from individuals under antihypertensive, antidiabetic or hypocholesterolemic medication were eliminated of the QTL analysis.
###end p 35
###begin p 36
###xml 116 118 116 118 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
###xml 119 121 119 121 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B28">28</xref>
Linkage disequilibrium (LD) and haplotype analysis was performed using THESIAS software based on the SEM algorithm [27,28]. This method allows to estimate haplotype frequencies and haplotype effects by comparison to a reference (the intercept) taken here as the most frequent one. For quantitative analysis, haplotypes effects are expressed as increases/decreases of the phenotypic mean with respect to the intercept's one; for qualitative analysis, results are expressed as Odds ratio (OR). All the quantitative studies were corrected by age and sex. In a first approximation, all haplotypes identified were computed but, in order to minimize loss of power, haplotypes with a frequency lower than 3% were excluded from further analysis.
###end p 36
###begin p 37
###xml 90 92 90 92 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B29">29</xref>
###xml 93 95 93 95 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B30">30</xref>
We have also performed a regression-based haplotype association test using Whap software [29,30] to confirm results obtained with the SEM approach. This software also allows executing a Monte-Carlo test to obtain the empirical p values. All values were standardized before the analysis according to software instructions.
###end p 37
###begin title 38
Results
###end title 38
###begin title 39
Allele frequencies and genotype distribution
###end title 39
###begin p 40
###xml 614 615 612 613 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T2">2</xref>
Polymorphism status and allele frequencies were determined in all 606 individuals. The observed allelic frequencies in our population were 0.74 for A allele in rs948976 A>G, 0.57 for G allele in rs4945140 G>A, 0.94 for C allele in rs223546 C>T and 0.80 for G allele in rs223549G>A. The rs223546 is the less informative one, with only 0.06 frequency for the T allele and an observed heterozygosity of 0.11. All genotype frequencies fit the Hardy-Weinberg equilibrium (p >/= 0.129). Genotype distribution and Pearson's goodness-of-fit chi-square test for deviation from Hardy-Weinberg equilibrium are shown in table 2.
###end p 40
###begin p 41
Genotype distribution and test for Hardy-Weinberg disequilibrium
###end p 41
###begin title 42
Quantitative genotype analysis
###end title 42
###begin p 43
###xml 129 130 129 130 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T3">3</xref>
In this analysis we have found significant differences in BMI values associated with the two markers of the first cluster (table 3). For the rs948976 A>G polymorphism, wild type homozygotes have the highest BMI values (means: AA, 27.4 +/- 3.7; AG, 26.6 +/- 4.1; GG, 26.8 +/- 3.5 kg/m2; p = 0.035, r2 = 1.5%), whereas the presence of the polymorphic A allele at the rs4945140 G>A locus is associated with increased BMI values, especially in the homozygous state (means: GG, 26.5 +/- 3.7; GA, 27.2 +/- 3.8; AA, 27.8 +/- 4.2 kg/m2; p = 0.041, r2 = 2.0%). The rs4945140 G>A marker is also associated with DBP values, being again the polymorphic A allele which confers increased risk (means: GG, 75.3 +/- 8.7; GA, 77.7 +/- 7.9; AA, 77.9 +/- 7.8 mmHg; p = 0.015, r2 = 2.0%). Finally, HDL-c levels are associated with rs223549G>A genotypes; raised HDL-c values are related to the A allele (means: GG, 58.7 +/- 17.2; GA, 64.0 +/- 21.4; AA, 65.9 +/- 18.8 mg/dl; p = 0.025, r2 = 1.7%). We have not find any other significant associations at genotype levels.
###end p 43
###begin p 44
###xml 35 40 35 40 <italic xmlns:xlink="http://www.w3.org/1999/xlink">locus</italic>
Genotype analysis at the calpain 5 locus
###end p 44
###begin p 45
For each genotype, means and standard deviations are shown. rs948976, allele 1:allele A; rs4945140 allele 1, allele G; rs223549 allele 1, allele G.
###end p 45
###begin title 46
Haplotype analysis
###end title 46
###begin p 47
###xml 108 110 108 110 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2 </sup>
###xml 174 176 174 176 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2 </sup>
###xml 276 278 276 278 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-5</sup>
###xml 393 394 393 394 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T4">4</xref>
###xml 458 459 458 459 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T5">5</xref>
###xml 522 523 522 523 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="supplementary-material" rid="S1">1</xref>
###xml 525 526 525 526 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="supplementary-material" rid="S2">2</xref>
###xml 528 529 528 529 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="supplementary-material" rid="S3">3</xref>
###xml 531 532 531 532 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="supplementary-material" rid="S4">4</xref>
###xml 534 535 534 535 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="supplementary-material" rid="S5">5</xref>
###xml 537 538 537 538 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="supplementary-material" rid="S6">6</xref>
###xml 540 541 540 541 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="supplementary-material" rid="S7">7</xref>
###xml 543 544 543 544 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="supplementary-material" rid="S8">8</xref>
###xml 546 547 546 547 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="supplementary-material" rid="S9">9</xref>
###xml 549 551 549 551 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="supplementary-material" rid="S10">10</xref>
###xml 553 555 553 555 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="supplementary-material" rid="S11">11</xref>
###xml 557 559 557 559 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="supplementary-material" rid="S12">12</xref>
###xml 561 563 561 563 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="supplementary-material" rid="S13">13</xref>
###xml 565 567 565 567 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="supplementary-material" rid="S14">14</xref>
###xml 569 571 569 571 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="supplementary-material" rid="S15">15</xref>
###xml 573 575 573 575 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="supplementary-material" rid="S16">16</xref>
###xml 577 579 577 579 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="supplementary-material" rid="S17">17</xref>
###xml 581 583 581 583 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="supplementary-material" rid="S18">18</xref>
###xml 585 587 585 587 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="supplementary-material" rid="S19">19</xref>
###xml 649 650 647 648 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 650 655 648 653 <sub xmlns:xlink="http://www.w3.org/1999/xlink">5d.f </sub>
###xml 714 715 710 711 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 715 720 711 716 <sub xmlns:xlink="http://www.w3.org/1999/xlink">5d.f </sub>
###xml 856 857 850 851 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 857 862 851 856 <sub xmlns:xlink="http://www.w3.org/1999/xlink">5d.f </sub>
The four polymorphisms analysed are in two LD blocks: rs948976 A>G and rs4945140 G>A in intron 1 (D' = -1, r2 = 0.26) and rs223546 C>T and rs223549G>A in intron 3 (D' = -1, r2 = 0.02), separated from each other by a recombination hot-spot (D' between blocks = 0, r2 = 7.8 x 10-5). With this LD pattern, nine different haplotypes are possible with frequencies ranging from 1.5% to 28.5% (table 4). The leading results of haplotype analysis are shown in table 5; the complete study is available online [see Additional files 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19]. The highest global haplotypic effect was found for DBP (chi25d.f = 14.96 with, p = 0.010) followed by total cholesterol (chi25d.f = 11.43, p = 0.043). There is also a trend toward being associated for BMI, but it did not reach the statistical significance level (chi25d.f = 10.8, p = 0.056). No significant global associations have been found for any of the other traits analysed (p >/= 0.081).
###end p 47
###begin p 48
###xml 21 33 21 33 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CAPN5 locus </italic>
Haplotypes formed at CAPN5 locus with Nt g.86, Nt g.344, Nt c.1320 and Nt c.1469 polymorphisms
###end p 48
###begin p 49
###xml 34 40 34 40 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CAPN5 </italic>
Effects of the main haplotypes of CAPN5 by comparison to the most frequent haplotype adjusted for age and sex
###end p 49
###begin p 50
Haplotype effects are expressed as increases or decreases with CIs and as % over the reference haplotype mean.
###end p 50
###begin p 51
###xml 57 63 57 63 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CAPN5 </italic>
###xml 383 384 381 382 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 705 706 701 702 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 706 711 702 707 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2d.f </sub>
###xml 809 815 805 811 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CAPN5 </italic>
###xml 884 901 880 897 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="supplementary-material" rid="S2">Additional file 2</xref>
According to the global haplotypic analysis, none of the CAPN5 haplotypes are consistently associated with BMI values and only the AA-CA haplotype shows a suggestive association (p = 0.086), being this result significant under de regression-based model (empirical p-value after 5.000 permutations = 0.039). We determined the frequency of the AA-CA haplotype in obese (BMI >/= 30 kg/m2, 148 individuals) and non-obese subjects, being this haplotype over-represented in obese population (OR = 1.63 [1.05-2.54], p = 0.029). The haplotype analysis of BMI values in the two clusters independently (intron 1 from one side and intron 3 from another) showed that only the first cluster is informative for BMI (chi22d.f 6.07, p = 0.048) according to the genotype analysis. We have not found evidence of association of CAPN5 alleles with abdominal obesity estimated by waist circumference [see Additional file 2].
###end p 51
###begin p 52
###xml 380 381 378 379 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 381 386 379 384 <sub xmlns:xlink="http://www.w3.org/1999/xlink">5d.f </sub>
With respect to blood pressure, haplotypes AG-CA (p = 0.0005) and GG-CG (p = 0.006) are related to a significant decrease of DBP values (-14.2% and -6.1%, respectively). The, independent analysis of the two clusters showed that the second one is not significant whereas the global measure of association of cluster 1 is of a similar magnitude that in the full-length analysis (chi25d.f = 7.84, p = 0.019)
###end p 52
###begin p 53
###xml 540 542 538 540 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="supplementary-material" rid="S10">10</xref>
###xml 547 549 545 547 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="supplementary-material" rid="S12">12</xref>
Haplotype GG-CA is associated with higher total (p = 0.001, +29.6%) and LDL-cholesterol (p = 0.008, +36.1%). In contrast, haplotype GG-CG is related to a reduction in both values (p = 0.029, -8.0% and p = 0.044, -10.3%). None of the regions are independently associated with the trait (global p >/= 0.090), suggesting that both are necessary to modulate the phenotype and explaining the absence of association in the genotype analysis. No associations have been found for HDL-c or TG levels in the haplotypic analysis [see Additional files 10 and 12].
###end p 53
###begin p 54
###xml 30 36 30 36 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CAPN5 </italic>
###xml 101 102 101 102 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="supplementary-material" rid="S5">5</xref>
###xml 104 105 104 105 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="supplementary-material" rid="S6">6</xref>
###xml 107 108 107 108 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="supplementary-material" rid="S7">7</xref>
###xml 351 357 347 353 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CAPN5 </italic>
###xml 482 484 478 480 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="supplementary-material" rid="S15">15</xref>
###xml 486 488 482 484 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="supplementary-material" rid="S16">16</xref>
###xml 490 492 486 488 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="supplementary-material" rid="S17">17</xref>
We have not found evidence of CAPN5 being related to glucose or insulin levels [see Additional files 5, 6, 7]. Although the AG-CA haplotype was significantly associated with fasting glucose and 2 h-glucose levels (p </= 0.034), the global haplotypic effect was not significant (p >/= 0.107). In this way, T2DM, IFG or IGT do not seem to be related to CAPN5 alleles, although the number of affected individuals is small (49, 77 and 74 individuals respectively) [see Additional files 15, 16, 17].
###end p 54
###begin p 55
###xml 354 355 352 353 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 355 360 353 358 <sub xmlns:xlink="http://www.w3.org/1999/xlink">5d.f </sub>
Considering metabolic syndrome under de ATPIII definition, we have found association with the obesity related AA-CA haplotype (p = 0.029, OR = 1.80 [1.06-3.06], n = 90), although the global haplotypic effect is not significant (p = 0.166). For the metabolic syndrome diagnosed following the IDF criteria, the global haplotypic effect was significant (chi25d.f = 11.74, p = 0.039), but only a suggestive protective effect for the GG-CG haplotype could be determined (OR = 0.63 [0.37-1.08], p = 0.092).
###end p 55
###begin title 56
Discussion
###end title 56
###begin p 57
###xml 50 56 50 56 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CAPN5 </italic>
###xml 391 393 391 393 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B31">31</xref>
###xml 394 396 394 396 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B32">32</xref>
In this population-based survey, we have isolated CAPN5 as a candidate gene for cardiovascular risk factors such as BMI, diastolic blood pressure and cholesterol. In addition, the haplotype related to obesity (AA-CA) is more frequent in individuals with metabolic syndrome (ATPIII criteria), supporting the role of obesity as an important underlying risk factor for cardiovascular diseases [31,32]. Two groups of haplotypes can be drawn regarding cardiovascular disease risk factors: protective haplotypes (GG-CG and AG-CA) and risk haplotypes (AA-CA and GG-CA).
###end p 57
###begin p 58
###xml 44 50 44 50 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CAPN5 </italic>
###xml 162 164 162 164 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B33">33</xref>
###xml 325 331 325 331 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CAPN5 </italic>
###xml 563 565 563 565 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 1154 1160 1154 1160 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CAPN5 </italic>
###xml 1251 1257 1251 1257 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CAPN5 </italic>
###xml 1344 1348 1344 1348 <italic xmlns:xlink="http://www.w3.org/1999/xlink">OMP </italic>
###xml 1468 1472 1468 1472 <italic xmlns:xlink="http://www.w3.org/1999/xlink">OMP </italic>
###xml 1562 1568 1562 1568 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CAPN5 </italic>
###xml 72 77 <span type="species:ncbi:9606">women</span>
###xml 106 111 <span type="species:ncbi:9606">women</span>
###xml 280 288 <span type="species:ncbi:9606">patients</span>
###xml 392 400 <span type="species:ncbi:9606">patients</span>
###xml 625 630 <span type="species:ncbi:9606">women</span>
###xml 699 704 <span type="species:ncbi:9606">women</span>
In a previous study, we analysed these four CAPN5 gene variants in PCOS women, an anovulatory disorder of women in which insulin resistance plays a central role [33]. In that work, the GG-CA haplotype, associated with cholesterol levels in this work, was over-represented in PCOS patients. In addition, we associated several CAPN5 haplotypes with phenotypic differences observed between PCOS patients, such as the presence of obesity (AA-CA) and familial antecedents of obesity (AA-CA and GG-CG), hypertension (AA-CA and GG-CG) and hypercholesterolemia (GG-CA). [18]. Presence of familial antecedents of hypertension in PCOS women is a frequent finding; the higher frequency of this haplotype among women with familial antecedents of hypertension suggested a hypertensive phenotype associated to this allele. However, in this work, a measure of the effect of this haplotype in a population-based analysis has revealed a blood pressure lowering effect of the GG-CG haplotype. It is possible that smaller sample size in PCOS study, the effect of PCOS phenotype or PCOS related alleles have been acting as confounding factors. Anyway, the identification of CAPN5 gene haplotypes affecting cardiovascular risk factors also in general population reinforce CAPN5 as a candidate gene for metabolic syndrome related phenotypes. It is unlikely that the OMP gene itself be causative for the described associations in our population, given that haplotype association analysis at OMP region (intron 3) was not significant for any of the traits analysed, being necessary the CAPN5 intron 1 region to modulate the phenotype.
###end p 58
###begin p 59
###xml 157 158 157 158 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 160 161 160 161 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 178 185 178 185 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CAPN10 </italic>
###xml 275 277 275 277 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B34">34</xref>
###xml 326 333 326 333 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CAPN10 </italic>
###xml 368 370 368 370 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B35">35</xref>
###xml 525 527 525 527 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B36">36</xref>
###xml 554 561 554 561 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CAPN10 </italic>
###xml 600 604 600 601 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#946;</italic>
###xml 739 741 736 738 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B37">37</xref>
###xml 978 980 975 977 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B38">38</xref>
###xml 40 46 <span type="species:ncbi:9606">humans</span>
###xml 78 83 <span type="species:ncbi:9606">human</span>
Little is known about CAPN5 function in humans. It is expressed in almost all human tissues, including testis, ovary, liver, heart, colon, kidney and brain [5][6]. Its homologue CAPN10 has been related to insulin secretion and action in both functional and genetic analyses [34]. Some authors have also pointed out a role for CAPN10 in adipocyte biology. Paul et al. [35] described how CAPN10 facilitates GLUT4 vesicle translocation during insulin-stimulated glucose uptake in adipocytes. Another report by Hoffstedt et al. [36] describes association of CAPN10 gene with the lipolytic sensitivity of beta3-adrenoreceptors in subcutaneous fat cells in overweight subjects. Calpains have been also associated with adipocyte differentiation [37]. Regarding hypertension, calpains have been involved in mitochondrial mechanisms of oxidative stress that leads to vascular dysfunction which causes systemic hypertension and compensatory cardiac stiffness and diastolic heart failure [38].
###end p 59
###begin p 60
###xml 23 32 23 32 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C.elegans</italic>
###xml 208 209 208 209 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 612 621 612 621 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C.elegans</italic>
###xml 683 692 683 692 <italic xmlns:xlink="http://www.w3.org/1999/xlink">knockout </italic>
###xml 767 773 767 773 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FEM1A </italic>
###xml 908 909 908 909 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 910 911 910 911 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 912 914 912 914 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B39">39</xref>
###xml 992 994 992 994 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B40">40</xref>
###xml 1338 1340 1338 1340 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B41">41</xref>
###xml 1341 1343 1341 1343 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B43">43</xref>
###xml 1524 1526 1524 1526 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B44">44</xref>
###xml 23 32 <span type="species:ncbi:6239">C.elegans</span>
###xml 537 542 <span type="species:ncbi:9606">human</span>
###xml 612 621 <span type="species:ncbi:6239">C.elegans</span>
###xml 692 696 <span type="species:ncbi:10090|species:ncbi:10095">mice</span>
###xml 788 795 <span type="species:ncbi:9606">patient</span>
###xml 848 853 <span type="species:ncbi:9606">human</span>
###xml 920 926 <span type="species:ncbi:9606">humans</span>
The CAPN5 ortologhe in C.elegans, TRA-3, mediates the proteolitic cleavage of TRA-2A, a transmembrane protein that binds and inhibits the activity of the male-promoting FEM proteins (FEM-1, FEM-2 and FEM-3) [7]. The proteolitic action of TRA-3 over TRA-2 protein; produce a soluble fragment that is delivered to the nucleus where it enhances the transcriptional activity of the zinc finger transcription factor TRA-1 which promotes female development. Because mechanisms of sexual differentiation are not conserved between nematodes and human, it is possible that this pathway has more general functions than in C.elegans. In fact, the finding of abnormal glucose homeostasis in the knockout mice for Fem1b gene, the identification of a germline missense mutation in FEM1A gene in a PCOS patient and the observation of FEM1A being downregulated in human Rhabdomyosarcoma cell lines, support this hypothesis [8,9,39]. In humans, CAPN5 is localized to the cytoplasma as well as to the nucleus [40]. It is possible that, in a similar way of its ortologue TRA-3, CAPN5 could act over nuclear proteins that affect DNA transcription such as transcription factors or related proteins. Calpains are known to cleave several transcription factors: c-Fos, c-Jun, Oct-1, p53 or C/EBP transcription factor family among others, are calpain substrates [41-43]. Calpains can also affect DNA transcription in an indirect way. For example, activation of NF-kappa B requires the proteolitic degradation of its inhibitor I kappa B by calpains [44].
###end p 60
###begin p 61
###xml 72 78 72 78 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CAPN5 </italic>
###xml 248 254 248 254 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CAPN5 </italic>
###xml 284 290 284 290 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CAPN5 </italic>
###xml 558 560 558 560 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B45">45</xref>
###xml 776 778 776 778 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B46">46</xref>
###xml 550 556 <span type="species:ncbi:9606">humans</span>
It is also possible that the identified associations are not related to CAPN5 gene itself, but other upstream gene in linkage disequilibrium with the polymorphic variants analysed. However, HapMap shows that LD block that includes the 5' region of CAPN5 is interrupted 29 kb upstream CAPN5 5'UTR. This region only includes the gene that codifies B3Gn-T6, a member of the N-acetylglucosaminyl transferase protein family related to muscular dystrophies, neoplastic disorders and altered glucose homeostasis, although B3Gn-T6 has never been analysed in humans [45]. The adjacent 5' LD block comprises 193 kb and includes the PHCA gene that codifies an alkaline phytoceramidase, an integral membrane protein related to protein biosynthesis and lipid membrane ceramide metabolism [46]. Beyond this region, is not probably to detect association with our marker selection. The absence of association in the independent cluster analysis of BMI, cholesterol levels and diastolic blood pressure with the markers of the second LD block that contains the OMP gene, makes improbable that the associations described here can be due to this intragenic gene. To elucidate this question, further analysis is being performed.
###end p 61
###begin title 62
Conclusion
###end title 62
###begin p 63
###xml 94 100 94 100 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CAPN5 </italic>
###xml 368 374 368 374 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CAPN5 </italic>
###xml 400 405 400 405 <italic xmlns:xlink="http://www.w3.org/1999/xlink">et al</italic>
###xml 408 410 408 410 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 526 532 526 532 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CAPN5 </italic>
###xml 43 48 <span type="species:ncbi:9606">women</span>
Results obtained from our analysis in PCOS women and this population-based study suggest that CAPN5 is a gene related to metabolic syndrome and related phenotypes such as obesity, hypertension and hypercholesterolemia, at least in the Spanish population. These results are in accordance with the evidence of linkage of T2DM within the chromosomal region that contains CAPN5 gene reported by Silander et al. [19]. However, a confirmation of our findings in independent populations is necessary to clearly establish the role of CAPN5 in metabolic syndrome.
###end p 63
###begin title 64
Abbreviations
###end title 64
###begin p 65
CVD: cardiovascular disease
###end p 65
###begin p 66
T2DM: type 2 diabetes mellitus
###end p 66
###begin p 67
MS: metabolic syndrome
###end p 67
###begin p 68
CAPN10: calpain 10
###end p 68
###begin p 69
CAPN5: calpain 5
###end p 69
###begin p 70
PCOS: polycystic ovary syndrome
###end p 70
###begin p 71
BMI: body mass index
###end p 71
###begin p 72
WC: waist circumference
###end p 72
###begin p 73
SBP: systolic blood pressure
###end p 73
###begin p 74
DBP: diastolic blood pressure
###end p 74
###begin p 75
IR: insulin resistance
###end p 75
###begin p 76
HOMA: homeostasis model assessment
###end p 76
###begin p 77
HDL: high density lipoprotein
###end p 77
###begin p 78
LDL: low density lipoprotein
###end p 78
###begin p 79
OGTT: oral glucose tolerance test
###end p 79
###begin p 80
IFG: impaired fasting glucose
###end p 80
###begin p 81
IGT: impaired glucose tolerance
###end p 81
###begin p 82
TGs: triglycerides
###end p 82
###begin p 83
LD: linkage disequilibrium
###end p 83
###begin p 84
OR: odds ratio
###end p 84
###begin title 85
Competing interests
###end title 85
###begin p 86
The authors ME Saez, R Ramirez-Lorca and A Ruiz have declared that conflicts of interest exist. Some of the work described here is subject to patent filings for diagnostics purposes (WO2005116247).
###end p 86
###begin title 87
Authors' contributions
###end title 87
###begin p 88
MES: has genotyped samples, analysed and interpreted data and draft the manuscript.
###end p 88
###begin p 89
RRL, FJM and AR: have contributed to conception and design of the study and revised the manuscript.
###end p 89
###begin p 90
MTML, JLGL, CZ, MJMC and MSR: have contributed to the acquisition and interpretation of data and revised the manuscript.
###end p 90
###begin p 91
All authors read and approved the final manuscript.
###end p 91
###begin title 92
Pre-publication history
###end title 92
###begin p 93
The pre-publication history for this paper can be accessed here:
###end p 93
###begin p 94

###end p 94
###begin title 95
Supplementary Material
###end title 95
###begin title 96
Additional File 1
###end title 96
###begin p 97
###xml 39 45 39 45 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CAPN5 </italic>
BMI. Haplotype association analysis of CAPN5 gene with BMI values using Thesias software.
###end p 97
###begin p 98
Click here for file
###end p 98
###begin title 99
Additional File 2
###end title 99
###begin p 100
###xml 55 61 55 61 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CAPN5 </italic>
Waist circumference. Haplotype association analysis of CAPN5 gene with waist circumference values using Thesias software.
###end p 100
###begin p 101
Click here for file
###end p 101
###begin title 102
Additional File 3
###end title 102
###begin p 103
###xml 39 45 39 45 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CAPN5 </italic>
SBP. Haplotype association analysis of CAPN5 gene with systolic blood pressure (SBP) values using Thesias software.
###end p 103
###begin p 104
Click here for file
###end p 104
###begin title 105
Additional File 4
###end title 105
###begin p 106
###xml 39 45 39 45 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CAPN5 </italic>
DBP. Haplotype association analysis of CAPN5 gene with diastolic blood pressure (DBP) values using Thesias software.
###end p 106
###begin p 107
Click here for file
###end p 107
###begin title 108
Additional File 5
###end title 108
###begin p 109
###xml 51 57 51 57 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CAPN5 </italic>
Fasting glucose. Haplotype association analysis of CAPN5 gene with fasting glucose values using Thesias software.
###end p 109
###begin p 110
Click here for file
###end p 110
###begin title 111
Additional File 6
###end title 111
###begin p 112
###xml 47 53 47 53 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CAPN5 </italic>
2 h-glucose. Haplotype association analysis of CAPN5 gene with glucose values after 2 hours from an oral glucose overload using Thesias software.
###end p 112
###begin p 113
Click here for file
###end p 113
###begin title 114
Additional File 7
###end title 114
###begin p 115
###xml 51 57 51 57 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CAPN5 </italic>
Fasting insulin. Haplotype association analysis of CAPN5 gene with fasting insulin values using Thesias software.
###end p 115
###begin p 116
Click here for file
###end p 116
###begin title 117
Additional File 8
###end title 117
###begin p 118
###xml 40 46 40 46 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CAPN5 </italic>
HOMA. Haplotype association analysis of CAPN5 gene with insulin resistance estimated using the Homeostasis Model Assessment method (HOMA) using Thesias software.
###end p 118
###begin p 119
Click here for file
###end p 119
###begin title 120
Additional File 9
###end title 120
###begin p 121
###xml 47 53 47 53 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CAPN5 </italic>
Cholesterol. Haplotype association analysis of CAPN5 gene with total cholesterol values using Thesias software.
###end p 121
###begin p 122
Click here for file
###end p 122
###begin title 123
Additional File 10
###end title 123
###begin p 124
###xml 41 47 41 47 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CAPN5 </italic>
HDL-c. Haplotype association analysis of CAPN5 gene with high-density lipoprotein cholesterol values using Thesias software.
###end p 124
###begin p 125
Click here for file
###end p 125
###begin title 126
Additional File 11
###end title 126
###begin p 127
###xml 41 47 41 47 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CAPN5 </italic>
LDL-c. Haplotype association analysis of CAPN5 gene with low-density lipoprotein cholesterol values using Thesias software.
###end p 127
###begin p 128
Click here for file
###end p 128
###begin title 129
Additional File 12
###end title 129
###begin p 130
###xml 39 45 39 45 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CAPN5 </italic>
TGs. Haplotype association analysis of CAPN5 gene with triglyceride values using Thesias software.
###end p 130
###begin p 131
Click here for file
###end p 131
###begin title 132
Additional File 13
###end title 132
###begin p 133
###xml 43 49 43 49 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CAPN5 </italic>
Obesity. Haplotype association analysis of CAPN5 gene with obesity defined as BMI >/= 30 using Thesias software.
###end p 133
###begin p 134
Click here for file
###end p 134
###begin title 135
Additional File 14
###end title 135
###begin p 136
###xml 61 67 61 67 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CAPN5 </italic>
Obesity with hypertension. Haplotype association analysis of CAPN5 gene with obesity associated with hypertension (BMI >/= 30 and SBP/DBP >/= 130/85) using Thesias software.
###end p 136
###begin p 137
Click here for file
###end p 137
###begin title 138
Additional File 15
###end title 138
###begin p 139
###xml 40 46 40 46 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CAPN5 </italic>
T2DM. Haplotype association analysis of CAPN5 gene with Type 2 Diabetes Mellitus (T2DM) using Thesias software.
###end p 139
###begin p 140
Click here for file
###end p 140
###begin title 141
Additional File 16
###end title 141
###begin p 142
###xml 39 45 39 45 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CAPN5 </italic>
IFG. Haplotype association analysis of CAPN5 gene with Impaired Fasting Glucose (IFG) using Thesias software.
###end p 142
###begin p 143
Click here for file
###end p 143
###begin title 144
Additional File 17
###end title 144
###begin p 145
###xml 39 45 39 45 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CAPN5 </italic>
IGT. Haplotype association analysis of CAPN5 gene with Impaired Glucose Tolerance (IGT) using Thesias software.
###end p 145
###begin p 146
Click here for file
###end p 146
###begin title 147
Additional File 18
###end title 147
###begin p 148
###xml 46 52 46 52 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CAPN5 </italic>
SM(ATPIII). Haplotype association analysis of CAPN5 gene with Metabolic Syndrome using the ATPIII definition using Thesias software.
###end p 148
###begin p 149
Click here for file
###end p 149
###begin title 150
Additional File 19
###end title 150
###begin p 151
###xml 43 49 43 49 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CAPN5 </italic>
SM(IDF). Haplotype association analysis of CAPN5 gene with Metabolic Syndrome using the International Diabetes Federation (IDF) definition using Thesias software.
###end p 151
###begin p 152
Click here for file
###end p 152
###begin title 153
Acknowledgements
###end title 153
###begin p 154
We are deeply grateful to Dr. David Tregouet for critical review of this article. We also thank Ana Salinas for technical support.
###end p 154
###begin p 155
Neocodex have been partially funded by the Ministerio de Ciencia y Tecnologia of Spain (FIT-010000-2003-36, FIT-010000-2003-89, FIT-0100002003-70, PTQ2003-0783 and PTQ2003-0549).
###end p 155
###begin p 156
This work has also been supported by grants FISS 03/1618 from Fondo de Investigaciones Sanitarias and a grant from Red de Centros RCMN (C03/08), Madrid, Spain.
###end p 156
###begin article-title 157
Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report
###end article-title 157
###begin article-title 158
The calpain system
###end article-title 158
###begin article-title 159
The therapeutic potential of the calpain family: new aspects
###end article-title 159
###begin article-title 160
###xml 36 58 <span type="species:ncbi:6239">Caenorhabditis elegans</span>
The tra-3 sex determination gene of Caenorhabditis elegans encodes a member of the calpain regulatory protease family
###end article-title 160
###begin article-title 161
A new subfamily of vertebrate calpains lacking a calmodulin-like domain: implications for calpain regulation and evolution
###end article-title 161
###begin article-title 162
###xml 42 45 <span type="species:ncbi:10116">rat</span>
###xml 50 55 <span type="species:ncbi:9606">human</span>
Molecular cloning and characterization of rat and human calpain-5
###end article-title 162
###begin article-title 163
###xml 59 69 <span type="species:ncbi:6239">C. elegans</span>
It ain't over till it's ova: germline sex determination in C. elegans
###end article-title 163
###begin article-title 164
###xml 62 66 <span type="species:ncbi:10090|species:ncbi:10095">mice</span>
Abnormal glucose homeostasis and pancreatic islet function in mice with inactivation of the Fem1b gene
###end article-title 164
###begin article-title 165
FEM1A is a candidate gene for polycystic ovary syndrome
###end article-title 165
###begin article-title 166
Genetic variation in the gene encoding calpain-10 is associated with type 2 diabetes mellitus
###end article-title 166
###begin article-title 167
Functional significance of the UCSNP-43 polymorphism in the CAPN10 gene for proinsulin processing and insulin secretion in nondiabetic Germans
###end article-title 167
###begin article-title 168
A calpain-10 gene polymorphism is associated with reduced muscle mRNA levels and insulin resistance
###end article-title 168
###begin article-title 169
Relationship of calpain-10 genotype to phenotypic features of polycystic ovary syndrome
###end article-title 169
###begin article-title 170
Comment: CAPN10 alleles are associated with polycystic ovary syndrome
###end article-title 170
###begin article-title 171
###xml 83 91 <span type="species:ncbi:9606">patients</span>
Specific CAPN10 gene haplotypes influence the clinical profile of polycystic ovary patients
###end article-title 171
###begin article-title 172
[Relationship between calpain-10 gene polymorphism, hypertension and plasma glucose]
###end article-title 172
###begin article-title 173
Association of the SNP-19 genotype 22 in the calpain-10 gene with elevated body mass index and hemoglobin A1c levels in Japanese
###end article-title 173
###begin article-title 174
Specific haplotypes of the CALPAIN-5 gene are associated with polycystic ovary syndrome
###end article-title 174
###begin article-title 175
A large set of Finnish affected sibling pair families with type 2 diabetes suggests susceptibility loci on chromosomes 6, 11, and 14
###end article-title 175
###begin article-title 176
[Prevalence of the metabolic syndrome (ATP-III criteria). Population-based study of rural and urban areas in the Spanish province of Segovia]
###end article-title 176
###begin article-title 177
Follow-up report on the diagnosis of diabetes mellitus
###end article-title 177
###begin article-title 178
###xml 130 133 <span type="species:ncbi:9606">man</span>
Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man
###end article-title 178
###begin article-title 179
Definition of metabolic syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition
###end article-title 179
###begin article-title 180
The metabolic syndrome-a new worldwide definition
###end article-title 180
###begin article-title 181
From genotypes to genes: doubling the sample size
###end article-title 181
###begin article-title 182
###xml 13 18 <span type="species:ncbi:9606">Human</span>
Institute of Human Genetics
###end article-title 182
###begin article-title 183
GeneCanvas
###end article-title 183
###begin article-title 184
A new algorithm for haplotype-based association analysis: the Stochastic-EM algorithm
###end article-title 184
###begin article-title 185
WHAP: haplotype-based association analysis
###end article-title 185
###begin article-title 186
Purcell lab
###end article-title 186
###begin article-title 187
Cardiovascular outcomes for obesity and metabolic syndrome
###end article-title 187
###begin article-title 188
Classification of obesity and assessment of obesity-related health risks
###end article-title 188
###begin article-title 189
###xml 22 27 <span type="species:ncbi:9606">women</span>
Metabolic syndrome in women with polycystic ovary syndrome
###end article-title 189
###begin article-title 190
Calpain-10: from genome search to function
###end article-title 190
###begin article-title 191
Calpain facilitates GLUT4 vesicle translocation during insulin-stimulated glucose uptake in adipocytes
###end article-title 191
###begin article-title 192
###xml 89 94 <span type="species:ncbi:9606">human</span>
Calpain-10 gene polymorphism is associated with reduced beta(3)-adrenoceptor function in human fat cells
###end article-title 192
###begin article-title 193
Role of calpain in adipocyte differentiation
###end article-title 193
###begin article-title 194
Mitochondrial mechanism of oxidative stress and systemic hypertension in hyperhomocysteinemia
###end article-title 194
###begin article-title 195
The Fem1a gene is downregulated in Rhabdomyosarcoma
###end article-title 195
###begin article-title 196
Inhibition of calpain cleavage of huntingtin reduces toxicity: accumulation of calpain/caspase fragments in the nucleus
###end article-title 196
###begin article-title 197
Degradation of C/EBPbeta in cultured myotubes is calpain-dependent
###end article-title 197
###begin article-title 198
Proteolysis of p53 protein by ubiquitous calpains
###end article-title 198
###begin article-title 199
Specific cleavage of transcription factors by the thiol protease, m-calpain
###end article-title 199
###begin article-title 200
Activation of NF-kappa B requires proteolysis of the inhibitor I kappa B-alpha: signal-induced phosphorylation of I kappa B-alpha alone does not release active NF-kappa B
###end article-title 200
###begin article-title 201
Proteomic approaches to analyze the dynamic relationships between nucleocytoplasmic protein glycosylation and phosphorylation
###end article-title 201
###begin article-title 202
###xml 40 45 <span type="species:ncbi:9606">human</span>
Cloning and characterization of a novel human alkaline ceramidase. A mammalian enzyme that hydrolyzes phytoceramide
###end article-title 202

